Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityOther Non-Current LiabilitiesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Goldenwell Biotech (GWLL) Cash & Equivalents (2019 - 2025)

Goldenwell Biotech's Cash & Equivalents history spans 7 years, with the latest figure at $45622.0 for Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 859.45% year-over-year to $45622.0; the TTM value through Sep 2025 reached $45622.0, up 859.45%, while the annual FY2024 figure was $49404.0, 7.19% down from the prior year.
  • Cash & Equivalents reached $45622.0 in Q3 2025 per GWLL's latest filing, down from $76507.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $248569.0 in Q1 2021 to a low of $4755.0 in Q3 2024.
  • Average Cash & Equivalents over 5 years is $87931.7, with a median of $45996.0 recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: tumbled 82.54% in 2022, then surged 859.45% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $213556.0 in 2021, then plummeted by 78.46% to $45996.0 in 2022, then rose by 15.73% to $53231.0 in 2023, then dropped by 7.19% to $49404.0 in 2024, then fell by 7.66% to $45622.0 in 2025.
  • Per Business Quant, the three most recent readings for GWLL's Cash & Equivalents are $45622.0 (Q3 2025), $76507.0 (Q2 2025), and $17127.0 (Q1 2025).